Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
generalAcute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) or t(16;16)(p13.1;q22), which results in the expression of the fusion protein CBFB-MYH11. This is seen in 7-9% of children with AML.
11
Centers
0
Active Trials
—
Cancer Funding
Top Centers for Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11(11)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive | 54.5 |
| 2 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive | 54.5 |
| 3 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive | 54.5 |
| 4 | Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive | 54.5 |
| 5 | Dartmouth Cancer CenterLebanon, NH NCI Comprehensive | 54.5 |
| 6 | University of Illinois Cancer CenterChicago, IL | 54.5 |
| 7 | Boston University Cancer CenterBoston, MA | 54.5 |
| 8 | Cancer Center at IllinoisUrbana, IL | 54.5 |
| 9 | Penn State Cancer InstituteHershey, PA | 54.5 |
| 10 | Northwell Health Cancer InstituteNew York, NY | 54.5 |
| 11 | Upstate Cancer CenterSyracuse, NY | 54.5 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →